Drug Profile
GSK 3439171A
Alternative Names: GSK3439171; GSK3439171ALatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action Prostaglandin synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In volunteers) in USA (PO, Capsule)
- 28 May 2023 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In volunteers) in USA (PO, Liquid)
- 04 May 2021 GSK 3439171A is still in phase I trials for Duchenne muscular dystrophy (In volunteers) in USA (PO, Capsule) (GlaxoSmithKline pipeline, May 2021)